The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content


(Tibor Kolley/)

Wednesday's analyst upgrades and downgrades

Inside the Market’s roundup of some of today’s key analyst actions. This file will be updated during the trading day. For breaking analyst actions prior to market open every day, read our Before the Bell morning report.

Investors should wait for a pullback before buying shares of Valeant Pharmaceuticals International Inc., Canaccord Genuity analyst Neil Maruoka said after the stock rallied more than 12 per cent Tuesday to a record high as the company provided pleasing guidance numbers.